N. Dathan

Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.

M. Santoro, A. Fusco, M. Pierotti, 1994, Oncogene.

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

al. et, M. Santoro, A. Fusco, 1995, Science.

Cell type-specific activation of actin genes in the early amphibian embryo

J. Gurdon, T. Mohun, N. Dathan, 1984, Nature.

Activated RET oncogene products induce maturation of xenopus oocytes.

M. Santoro, A. Fusco, D. Grieco, 1995, Oncogene.

Activated RET/PTC oncogene elicits immediate early and delayed response genes in PC12 cells.

G. D. Vita, M. Santoro, A. Fusco, 1995, Oncogene.

A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B.

M. Cosma, L. Quadro, V. Colantuoni, 1996, The Biochemical journal.

Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential.

M. Santoro, A. Fusco, R. Melillo, 1997, Endocrinology.

RET/PTC activation in human thyroid carcinomas

M. Santoro, A. Fusco, V. Colantuoni, 1995, Journal of endocrinological investigation.